Overview
Cyclooxygenase-2 (COX-2) is the inducible enzyme that converts arachidonic acid to prostaglandin H₂ — the precursor of prostaglandin E₂ (PGE₂), prostacyclin, and thromboxane. Unlike COX-1 (constitutive, homeostatic), COX-2 is transcriptionally induced by nf kappa b during inflammation and is the primary pharmacological target of NSAIDs (aspirin, ibuprofen) and selective COX-2 inhibitors (celecoxib). With 36 file mentions, COX-2 is one of the most referenced inflammatory enzymes in the vault.
The Metal → NF-kB → COX-2 → PGE₂ Cascade
This is the core inflammatory pathway connecting metal exposure to prostaglandin-mediated disease:
- Heavy metals (cadmium, nickel, lead, arsenic) generate ROS → oxidize IkB kinase → activate nf kappa b [1] [2].
- NF-kB translocates to the nucleus → transcribes COX-2, IL-6, TNF-alpha, il 1beta, and iNOS.
- COX-2 converts membrane arachidonic acid to PGE₂.
- PGE₂ drives vasodilation, edema, pain, fever, and — critically — promotes tumor cell proliferation, angiogenesis, and immune evasion in cancer.
The identical cascade is triggered by microbial LPS via TLR4 — making metal-driven and microbiome-driven COX-2 activation molecularly indistinguishable.
Microbiome Connection
- LPS/TLR4: Gram-negative bacterial LPS activates TLR4 → NF-kB → COX-2 → PGE₂. Endotoxemia from gut barrier failure provides chronic LPS exposure → chronic COX-2 activation [3].
- Periodontal pathogens: porphyromonas gingivalis LPS and gingipains activate COX-2 in gingival and vascular tissue, linking oral dysbiosis to cardiovascular inflammation [3].
- Endometriosis: COX-2-derived PGE₂ drives endometriotic lesion proliferation, angiogenesis, and pain. Fecal metabolomics show altered arachidonic acid metabolism in endometriosis [4].
- Schizophrenia: COX-2 inhibition (celecoxib) as adjunctive therapy in schizophrenia — targeting the inflammation-neurodegeneration axis [5].
NSAIDs: The COX-2 Paradox
NSAIDs block COX-2, reducing PGE₂ and inflammation. But they also:
- Damage gut epithelium → increased intestinal permeability → more LPS translocation → more COX-2 activation — a paradoxical feed-forward loop.
- Disrupt the gut microbiome → dysbiosis → loss of colonization resistance.
- Block prostaglandin-dependent mucosal protection in the stomach and small intestine.
This is why aspirin and ibuprofen reduce inflammation systemically while causing GI injury locally — the microbiome pays the price for COX-2 inhibition.
Cancer Connection
COX-2 overexpression is found in ~85% of colorectal cancers and correlates with tumor grade, stage, and metastasis. COX-2-derived PGE₂:
- Promotes tumor cell proliferation via beta-catenin and PI3K/Akt.
- Drives angiogenesis via VEGF induction.
- Suppresses anti-tumor immunity (PGE₂ inhibits dendritic cell maturation and NK cell function).
- Aspirin's CRC chemopreventive effect is primarily via COX-2 inhibition.
Cross-References
- nf kappa b — transcriptional driver of COX-2 expression
- arachidonic acid — COX-2 substrate
- inflammation — COX-2/PGE₂ as core inflammatory effector
- aspirin — COX-2 inhibitor with dual GI injury/chemopreventive profile
- endotoxemia — LPS/TLR4 → COX-2 activation
- endometriosis — PGE₂-driven lesion proliferation
- colorectal cancer — COX-2 overexpression in ~85% of CRC
- lipid peroxidation — arachidonic acid also subject to non-enzymatic oxidation